CTOs on the Move

OpenTrons

www.opentrons.com

 
We make robots for biologists. Our mission is to provide the scientific community with a common platform to easily share protocols and reproduce each other`s results. Our robots automate experiments that would otherwise be done by hand, allowing our community to spend more time pursuing answers to some of the 21st century`s most important questions.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.opentrons.com
  • 45-18 Court Square West
    Long Island City, NY USA 11101
  • Phone: 857.577.7656

Executives

Name Title Contact Details

Funding

OpenTrons raised $10M on 03/27/2018

Similar Companies

Cybin

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.

DynamiCure

DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates.

BiomedAIliance

BiomedAIliance is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SciMed Technologies

SciMed Technologies Inc. is a Edmonton, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GrayBug

GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.